down arrow

Stella Pharma Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3399680002
JPY
241.00
-6 (-2.43%)

Dec 12

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
GNI Group Ltd.
OncoTherapy Science, Inc.
Cyfuse Biomedical KK
MEDINET Co., Ltd.
SUSMED, Inc.
Stella Pharma Corp.
Oncolys BioPharma, Inc.
Chiome Bioscience, Inc.
StemCell Institute
Peptidream, Inc.
Carna Biosciences, Inc.
Why is Stella Pharma Corp. ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -234.76% of over the last 5 years
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -55.86%, its profits have risen by 81.6%
4
Below par performance in long term as well as near term
  • Along with generating -55.86% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Stella Pharma Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Stella Pharma Corp.
-55.86%
-0.66
50.93%
Japan Nikkei 225
27.57%
1.07
25.74%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
65.01%
EBIT Growth (5y)
-234.76%
EBIT to Interest (avg)
-188.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.11
Tax Ratio
2.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.85
EV to EBIT
-109.86
EV to EBITDA
-178.57
EV to Capital Employed
12.91
EV to Sales
10.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11.75%
ROE (Latest)
-4.39%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company
NET PROFIT(HY)

At JPY 76.15 MM has Grown at 116.7%

NET SALES(HY)

Higher at JPY 799.36 MM

ROCE(HY)

Highest at -4.71%

RAW MATERIAL COST(Y)

Fallen by -23.9% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 0.1%

-19What is not working for the Company
NET SALES(Q)

At JPY 92.4 MM has Fallen at -61.54%

PRE-TAX PROFIT(Q)

At JPY -155.97 MM has Fallen at -352.51%

NET PROFIT(Q)

At JPY -156.68 MM has Fallen at -345.08%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.48%

INTEREST(Q)

Highest at JPY 1.45 MM

Here's what is working for Stella Pharma Corp.
Inventory Turnover Ratio
Highest at 0.1%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -23.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Stella Pharma Corp.
Net Sales
At JPY 92.4 MM has Fallen at -61.54%
over average net sales of the previous four periods of JPY 240.26 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit
At JPY -155.97 MM has Fallen at -352.51%
over average net sales of the previous four periods of JPY -34.47 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit
At JPY -156.68 MM has Fallen at -345.08%
over average net sales of the previous four periods of JPY -35.2 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Interest
Highest at JPY 1.45 MM
in the last five periods and Increased by 7.87% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debtors Turnover Ratio
Lowest at 2.48%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."